Quantcast
Last updated on April 20, 2014 at 5:20 EDT

Latest Angiogenesis Stories

2013-01-29 08:31:28

SAN DIEGO, Jan. 29, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced a presentation at the 2013 Phacilitate Annual Cell & Gene Therapy Forum in Washington, DC. The Company's presentation, "Optimizing Phase III Trial Design for Generx® (Ad5FGF-4)" by Cardium's Chief Scientific Officer, Gabor M. Rubanyi, M.D., Ph.D. outlined the current scientific knowledge about the mechanistic basis of adaptive coronary collateral growth, the biological processes to be...

2013-01-04 08:22:33

ROCKVILLE, Md., Jan. 4, 2013 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company, announced today the initiation of a second site for its Phase 2 study of ENMD-2076 in triple-negative breast cancer (TNBC). Kathy Miller, MD, Associate Professor at the Melvin and Bren Simon Cancer Center at Indiana University serves as the investigator for the study. Indiana University joins the University of Colorado Cancer Center where the Phase 2 study is already...

2013-01-03 18:14:30

After recently announcing success in eliminating melanoma metastasis in laboratory experiments, scientists at Virginia Commonwealth University Massey Cancer Center have made another important discovery in understanding the process by which the gene mda-9/syntenin contributes to metastasis in melanoma (the spread of skin cancer) and possibly a variety of other cancers. Published in the journal Cancer Research, the study demonstrated that mda-9/syntenin is a key regulator of angiogenesis,...

2013-01-03 04:20:26

DIEPENBEEK, Belgium, January 3, 2013 /PRNewswire/ -- Amakem NV, a kinase platform company focusing on ophthalmology, today announces it has secured a EUR1.4M grant from the Flemish Agency for Innovation by Science and Technology (IWT), to apply its Localized Drug Action technology to the discovery and development of novel kinase inhibitor-based therapies for Inflammatory Bowel Diseases (IBD). IBD is a chronic, relapsing inflammatory disease of the gastrointestinal tract...

2012-11-29 08:28:35

NEW YORK and SIENA, Italy, Nov. 29, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. and Philogen S.p.A. today announced that they have commenced pre-clinical development of Philogen's L19 antibody construct labeled with actinium 225 as a therapeutic payload. The L19 antibody targets newly formed blood vessels that otherwise allow cancers to grow. If successful, this approach will further expand the field of use of alpha emitters. Clinical trials of drug candidates based on alpha...

2012-11-26 08:23:55

ROCKVILLE, Md., Nov. 26, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing targeted therapeutics for the treatment of cancer, announced today the publication of favorable results of a preclinical study in breast cancer of its oral Aurora A/angiogenic kinase inhibitor, ENMD-2076. (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO ) The article, entitled "Predictive Biomarkers of Sensitivity to the Aurora and...

2012-11-19 08:28:51

SAN DIEGO, Nov. 19, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced a winning patent decision in Europe and successful resolution of a long-standing competition between Cardium and its licensor the University of California, and Boston Scientific Corporation (NYSE: BSX) and its licensor Arch Development, over rights to key methods for the application of cardiovascular gene therapy to the treatment of coronary heart disease, as is employed in Cardium's Generx(®)...

2012-11-14 08:31:33

ROCKVILLE, Md., Nov. 14, 2012 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and nine-month periods ending September 30, 2012. (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO ) EntreMed reported a net loss for the third quarter of 2012 of ($1.2 million), or ($0.05) per share. This compares with a net loss of ($1.3 million), or ($0.13) per...

2012-11-06 08:29:19

SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today reported that uniQure's Glybera(®) (alipogene tiparvovec) approval by the European Commission, the first gene therapy approval by a major health regulatory authority, represents a significant milestone and validation for the gene therapy industry. Glybera(®) is a treatment for patients diagnosed with an inherited metabolic disease called familial lipoprotein lipase deficiency (LPLD or familial...

New Blood-vessel-generating Cell With Therapeutic Potential Discovered
2012-10-17 10:39:06

Researchers at the University of Helsinki, Finland, believe they have discovered stem cells that play a decisive role in new blood vessel growth. If researchers learn to isolate and efficiently produce these stem cells found in blood vessel walls, the cells offer new opportunities in the treatment of cardiovascular diseases, cancer and many other diseases. The study will be published in the PLOS Biology journal on 16 October 2012. The growth of new blood vessels, also known as...